Maze Therapeutics (MAZE) Net Margin (2024 - 2026)
Maze Therapeutics (MAZE) reported Net Margin of 97.98% for Q1 2026, down 477.09% sequentially from 25.98% in Q4 2024.
Maze Therapeutics (MAZE) Net Margin (2024 - 2026) Analysis & Trends
Maze Therapeutics (MAZE) has 2 years of Net Margin data on file, last reported at 97.98% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin changed N/A year-over-year to 97.98%; the trailing twelve-month figure through Mar 2026 stood at 451.97% (down 42092.0% YoY), and the FY2024 full-year result was 22.7%, changed N/A from the prior year.
- Net Margin declined to 97.98% in Q1 2026, from 25.98% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 927.04% in Q2 2024 to a low of 989.24% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Maze Therapeutics | 1.49 Bn | 1.49 Bn | 18.21 Mn | -97.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -97.98% |
| Dec 31, 2024 | 25.98% |
| Sep 30, 2024 | -989.24% |
| Jun 30, 2024 | 927.04% |